Post by Lonza

We have announced a new licensing agreement with InduPro to advance next-generation antibody-drug conjugate (ADC) therapeutics supporting the advancement of highly targeted cancer therapies. By combining our clinically validated bioconjugation platforms and linker-payload technologies with InduPro’s proprietary bispecific antibody capabilities, the collaboration aims to develop highly targeted ADCs designed to improve selectivity and therapeutic potential in complex cancers. Read more: https://lnkd.in/eTyxCffD #Lonza #CDMO #ADCs #Oncology #Bioconjugation #PharmaceuticalManufacturing